Glycosylation status of serum immunoglobulin G in patients with prostate diseases

Cancer Medicine

Volumn 5, Issue 6, 2016, Pages 1137-1146

  Kazuno, Saiko ^a   Furukawa, Jun Ichi ^b   Shinohara, Yasuro ^b   Murayama, Kimie ^a   Fujime, Makoto ^c   Ueno, Takashi ^a   Fujimura, Tsutomu ^a,d  

^a Department of Statistics for the Data Center Operations Office Japan Clinical Oncology Group Data Center Center for Research Administration and Support   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

IgG; mass spectrometry; N linked glycan; prostate cancer; PSA

Indexed keywords

AGGLUTININ; IMMUNOGLOBULIN G; LECTIN; N ACETYLGLUCOSAMINE;

ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; GLYCOSYLATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LIMIT OF QUANTITATION; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN BINDING; SAMBUCUS NIGRA; SURFACE PLASMON RESONANCE;

EID: 84991522885     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.662     Document Type: Article

References (33)

1. Candido, J., and T. Hagemann. 2013. Cancer-related inflammation. J. Clin. Immunol. 33 Suppl1:S79–S84.
2. Gabay, C., and I. Kushner. 1999. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340:448–464.
3. Chen, Y., B. K. Lim, S. C. Peh, et al. 2008. Profiling of serum and tissue high abundance acute-phase proteins of patients with epithelial and germ line ovarian carcinoma. Proteome Sci. 6:20.
4. Peracaula, R., A. Sarrats, and P. M. Rudd. 2010. Liver proteins as sensor of human malignancies and inflammation. Proteomics Clin. 4:426–431.
5. Gornik, O., and G. Lauc. 2008. Glycosylation of serum proteins in inflammatory diseases. Dis. Markers 28:267–278.
6. Dempsey, E., and P. M. Rudd. 2012. Acute phase glycoproteins: bystanders or participants in carcinogenesis? Ann. N. Y. Acad. Sci. 1253:122–132.
7. McCarthy, C., R. Saldova, M. R. Wormald, et al. 2014. The role and importance of glycosylation of acute phase proteins with focus on alpha-1 antitrypsin in acute and chronic inflammatory conditions. J. Proteome Res. 13:3131–3143.
8. Zhang, Y., J. Jiao, P. Yang, et al. 2014. Mass spectrometry-based N-glycoproteomics for cancer biomarker discovery. Clin. Proteomics 11:18.
9. Tarro, G., A. Perna, and C. Esposito. 2005. Early diagnosis of lung cancer by detection of tumor liberated protein. J. Cell. Physiol. 203:1–5.
10. Tanyi, J. L., and N. Scholler. 2012. Oncology biomarkers for gynecologic malignancies. Front Biosci. (Elite Ed) 4:1097–1110.
11. Ueda, K. 2013. Glycoproteomic strategies: From discovery to clinical application of cancer carbohydrate biomarkers. Proteomics Clin. Appl. 7:607–617.
12. Jemal, A., R. Siegel, E. Ward, et al. 2009. Cancer statistics 2009. CA Cancer J. Clin. 59:225–249.
13. Krumholtz, J. S., G. F. Carvalhal, C. G. Ramos, et al. 2002. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology 60:469–474.
14. Pelzer, A. E., J. Bektic, T. Akkad, S. Ongarello, G. Schaefer, C. Schwentner, et al. 2007. Under diagnosis and over diagnosis of prostate cancer in a screening population with serum PSA 2–10 ng/mL. J. Urol. 178:93–97.
15. Saito, S., S. Egawa, M. Endoh, et al. 2005. RM2 antigen (beta1,4-GalNAc-disialyl-Lc4) as a new marker for prostate cancer. Int. J. Cancer 115:105–113.
16. Saito, S., Y. Murayama, Y. Pan, et al. 2008. Haptoglobin-beta chain defined by monoclonal antibody RM2 as a novel serum marker for prostate cancer. Int. J. Cancer 123:633–640.
17. Fujimura, T., Y. Shinohara, B. Tissot, et al. 2008. Glycosylation status of haptoglobin in sera of patients with prostate cancer vs. benign prostate disease or normal subjects. Int. J. Cancer 122:39–49.
18. Okuyama, N., Y. Ide, M. Nakano, et al. 2006. Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int. J. Cancer 118:2803–2808.
19. Nakano, M., T. Nakagawa, T. Ito, et al. 2008. Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers. Int. J. Cancer 122:2301–2309.
20. Kudo, T., H. Nakagawa, M. Takahashi, et al. 2007. N-glycan alterations are associated with drug resistance in human hepatocellular carcinoma. Mol. Cancer. 6:32.
21. Yoon, S. J., S. Y. Park, P. C. Pang, et al. 2010. N-glycosylation status of beta-haptoglobin in sera of patients with prostate cancer vs. benign prostate diseases. Int. J. Oncol. 36:193–203.
22. Kazuno, S., T. Fujimura, T. Arai, et al. 2011. Multi-sequential surface plasmon resonance analysis of haptoglobin-lectin complex in sera of patients with malignant and benign prostate diseases. Anal. Biochem. 419:241–249.
23. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685.
24. Meyer-Siegler, K. L., K. A. Iczkowski, L. Leng, et al. 2006. Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J. Immunol. 177:8730–8739.
25. Mengus, C., C. Le Magnen, E. Trella, et al. 2011. Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer. J. Transl. Med. 9:162.
26. Singh, R. K., and B. L. Lokeshwar. 2011. The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth. Cancer Res. 71:3268–3277.
27. Radhakrishnan, P., V. Chachadi, M. F. Lin, et al. 2011. TNFα enhances the motility and invasiveness of prostatic cancer cells by stimulating the expression of selective glycosyl- and sulfotransferase genes involved in the synthesis of selectin ligands. Biochem. Biophys. Res. Commun. 409:436–441.
28. Saldova, R., M. R. Wormald, R. A. Dwek, et al. 2008. Glycosylation changes on serum glycoproteins in ovarian cancer may contribute to disease pathogenesis. Dis. Markers 25:219–232.
29. Higai, K., N. Miyazaki, Y. Azuma, et al. 2006. Interleukin-1beta induces sialyl Lewis X on hepatocellular carcinoma HuH-7 cells via enhanced expression of ST3Gal IV and FUT VI gene. FEBS Lett. 580:6069–6075.
30. Jefferis, R. 2009. Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discov. 8:226–234.
31. Huhn, C., M. H. Selman, L. R. Ruhaak, et al. 2009. IgG glycosylation analysis. Proteomics 9:882–913.
32. Saldova, R., L. Royle, C. M. Radcliffe, et al. 2007. Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology 17:1344–1356.
33. Saldova, R., Y. Fan, J. M. Fitzpatrick, et al. 2011. Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology 21:195–205.